NCT05190562

CompletedPhase 4

Effectiveness of Zinc Supplementation in Management of Patie...

mariam hamouda Source

ClinicalTrials.gov

Compare

Other study identifiers

Sponsor study identifier

FDASU-RECD-111

Study Type

interventional

Actual enrollment (reported)

48

Locations

1 country

Sites

1

Timeline

Study Start

September 6, 2021

Actual (reported)

Primary Completion

January 30, 2022

Actual (reported)

Study Completion

May 30, 2023

Actual (reported)

Brief Summary

Effectiveness of Zinc Supplementation in management of patients with symptomatic Benign Migratory Glossitis. Zinc supplements seems to be a therapeutic option as Migratory glossitis is a chronic disease knowing that it needs no treatment. Zinc deficiency can probably be a causative factor in filiform papillae atrophy. Studies have mentioned the role of zinc in wound healing and maintaining a healthy epithelium, as well as regeneration of filiform papillae. Geographic tongue is a disorder that affects the lingual papillae. It has been shown that zinc sulfate can contribute to the treatment of geographic tongue positively.

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: completed
Actual enrollment (reported): 48 participants
Study completion date: May 30, 2023
Actual (reported)
Listed locations: 1 countries · 1 sites

Trial Relationships

Click on a node to explore related trials.

Some registry-reported names shown below are not yet linked in this graph.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

Study Start
September 6, 2021
Actual (reported)
First Submitted
December 31, 2021
Actual (reported)
First Posted
January 13, 2022
Actual (reported)
Primary Completion
January 30, 2022
Actual (reported)
Study Completion
May 30, 2023
Actual (reported)

Last Updated: August 1, 2023
Status Verified: July 2023
Last Update Submitted: July 29, 2023

Conditions

Benign Migratory Glossitis

Keywords

Benign Migratory GlossitisZincGeographic tongue

Outcome Measures

Primary Outcomes (2)

Clinical Score
the size of atrophic areas
change from baseline at 8 weeks
Subjective Scale
intensity of symptoms
change from baseline at 8 weeks

Secondary Outcomes (1)

Biochemical
change from baseline at 4 weeks

Study Arms (1)

Zinc Sulphate

EXPERIMENTAL

Zinc Sulphate 25 Mg once daily for one month

Drug: Zinc Sulfate 110 MG (Zinc 25 MG) Oral Tablet

Interventions

Zinc Sulfate 110 MG (Zinc 25 MG) Oral TabletDrug

Zinc sulfate is an inorganic compound. It is used as a dietary supplement to treat zinc deficiency and to prevent the condition in those at high risk

Also known as: Octozinc

Zinc Sulphate

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years - 60 Years

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64)

You may qualify if:

Both genders are eligible.
Adults above 18 years old.

Sponsors & Collaborators

mariam hamouda
Otherlead

Study Sites (1)

Ain Shams University

Cairo, 12345, Egypt

MeSH Terms

Conditions

Glossitis, Benign Migratory

Interventions

Zinc SulfateZincTablets

Condition Hierarchy (Ancestors)

GlossitisTongue DiseasesMouth DiseasesStomatognathic Diseases

Intervention Hierarchy (Ancestors)

SulfatesSulfuric AcidsSulfur AcidsSulfur CompoundsInorganic Chemicals

Study Officials

Suzan Seif Allah, Professor
Ain Shams University
STUDY DIRECTOR

Enrollment

48 participants (actual enrollment reported by the registry).

Study Design

Study Type: interventional
Phase: phase 4
Allocation: NA
Masking: NONE
Purpose: TREATMENT
Intervention Model: SINGLE GROUP
Sponsor Type: OTHER
Responsible Party: SPONSOR INVESTIGATOR
PI Title: The Principal Investigator

Study Record Dates

First Submitted

December 31, 2021

First Posted

January 13, 2022

Study Start

September 6, 2021

Actual (reported)

Patients who presented at the control checkup with constant atrophic areas with raised keratotic margins.

Patients who diagnosed with symptomatic geographic tongue.

You may not qualify if:

Patients with anemia, oral candidiasis, and indicators for localized irritations (dental caries, affected teeth, sharp teeth edges, dental calculus, faulty dental fillings, and faulty prosthetic procedures).
Psoriatic patients.
Vulnerable patients (Prisoners, persons with mental disabilities or physical handicaps, children, neonates and pregnant women)

Contact the study team to confirm eligibility.

Zinc Compounds

Metals, Heavy

Elements

Transition Elements

Metals

Dosage Forms

Pharmaceutical Preparations

Primary Completion

January 30, 2022

Actual (reported)

Study Completion

May 30, 2023

Actual (reported)

Last Updated

August 1, 2023

Record last verified: 2023-07

Data Sharing

IPD Sharing: Will not share

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT05190562
Data provider: ClinicalTrials.gov
Source updated: 2023-08-01
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:35:26 UTC

Locations

EG(1)

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (2)

Secondary Outcomes (1)

Study Arms (1)

Zinc Sulphate

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Intervention Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations